Loading...

Novacyt S.A.

ALNOV.PA•EURONEXT
Healthcare
Medical - Devices
€0.48
€-0.01(-2.34%)

Novacyt S.A. (ALNOV.PA) Stock Overview

Explore Novacyt S.A.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.9/100

Key Financials

Market Cap33.9M
P/E Ratio-1.46
EPS (TTM)$-0.64
ROE-0.23%
Fundamental Analysis

AI Price Forecasts

1 Week$0.60
1 Month$0.38
3 Months$0.27
1 Year Target$0.39

ALNOV.PA Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Novacyt S.A. (ALNOV.PA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.39.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.46 and a market capitalization of 33.9M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for ALNOV.PAStats details for ALNOV.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ALNOV.PAAnalyst Recommendations details for ALNOV.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. It serves hospitals and corporates. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.

CEO

Lyn Dafydd Rees

Employees

234

Headquarters

13 Avenue Morane Saulnier, Le Vésinet

Founded

2012

Frequently Asked Questions

;